Skip to content

Clinical trials

Vision Disorders trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Vision Disorders Country / region: China Clear all

28 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20121
20133
20143
20162
20182
20195
20201
20221
20232
20243
20253
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Recruiting6
Unknown status5
Not yet recruiting2
Active, not recruiting2
Terminated2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals8
Sun Yat-sen University4
Shanghai Eye Disease Prevention and Treatment Center3
Zhongshan Ophthalmic Center, Sun Yat-sen University2
Evidence Based Cataract Study Group1
Eye & ENT Hospital of Fudan University1
First Affiliated Hospital of Guangxi Medical University1
Northeast Normal University1
Qilu Hospital of Shandong University1
Second Affiliated Hospital of Wenzhou Medical University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Vision Disorders28
Macular Edema5
Blindness4
Macular Degeneration4
Retinal Vein Occlusion4
Eye Diseases3
Wet Macular Degeneration3
Cataract2
Geographic Atrophy2
Myopia2

Trials

Showing 51 to 28 of 28. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.